Sign Out
Eltrombopag was not teratogenic when studied in pregnant rats and rabbits but caused a low incidence of cervical ribs (a fetal variation) and reduced fetal body weight at doses that were maternally toxic.
There are no adequate and well-controlled studies of Revolade in pregnant women. The effect of Revolade on human pregnancy is unknown. Revolade should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.
It is not known whether eltrombopag is excreted in human milk. Revolade is not recommended for nursing mothers unless the expected benefit justifies the potential risk to the infant.
